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CRM197 is an enzymatically inactive and nontoxic form of
diphtheria toxin that contains a single amino acid substitution
(G52E). Being naturally nontoxic, CRM197 is an ideal carrier protein
for conjugate vaccines against encapsulated bacteria and is
currently used to vaccinate children globally against Haemophilus
influenzae, pneumococcus, and meningococcus. To understand the
molecular basis for lack of toxicity in CRM197, we determined the
crystal structures of the full-length nucleotide-free CRM197 and of
CRM197 in complex with the NAD hydrolysis product nicotinamide
(NCA), both at 2.0-Å resolution. The structures show for the first
time that the overall fold of CRM197 and DT are nearly identical
and that the striking functional difference between the two pro-
teins can be explained by a flexible active-site loop that covers
the NAD binding pocket. We present the molecular basis for the
increased flexibility of the active-site loop in CRM197 as unveiled
by molecular dynamics simulations. These structural insights, com-
bined with surface plasmon resonance, NAD hydrolysis, and differ-
ential scanning fluorimetry data, contribute to a comprehensive
characterization of the vaccine carrier protein, CRM197.
Diphtheria is a contagious respiratory disease that was a majorcause of death among children around the world until mass
vaccination was introduced in the 1920s. Although diphtheria has
now been virtually eliminated in the industrialized world, rare
outbreaks still occur worldwide (1, 2). Corynebacterium diphther-
iae was shown to be the causative agent of diphtheria by Loeffler
in 1885 (3), and Roux and Yersin showed that an extracellular
toxin, diphtheria toxin (DT) secreted by C. diphtheriae is respon-
sible for toxicity (4). The formaldehyde-treated detoxified form
of DT, diphtheria toxoid, has been successfully used for mass vac-
cination and is still widely used as a component of combination
vaccines (5, 6).
A major contribution to the understanding of the mode of ac-
tion of DTwas the discovery of mutated forms in the early 1970s
(7). Several phages encoding mutants of DT, named cross-reac-
tive materials (CRMs), were isolated following nitrosoguanidine-
based mutagenesis of the phage containing the gene encoding
DT. Being naturally nontoxic, CRMs were immediately recog-
nized as having great potential for vaccine development. The
most important CRM identified was CRM197, an enzymatically
inactive and nontoxic form of DT that contains a single amino
acid substitution from Glycine to Glutamate in position 52 (8).
Subsequently CRM197 was found to be an ideal carrier for con-
jugate vaccines against encapsulated bacteria. Here, the carrier
protein is covalently linked to poorly immunogenic and T-cell-in-
dependent capsular polysaccharides, thus creating T-cell-depen-
dent conjugate antigens that are highly immunogenic in infants
(9–11).
Vaccines containing CRM197 as a carrier protein have been
successfully used to immunize hundreds of millions of children.
Such vaccines currently include Menveo®, a recently approved
tetravalent conjugate vaccine against serogroups A-C-W135-Y
of Neisseria meningitidis, Menjugate® and Meningitec® (against
serotype C of N. meningitidis), Vaxem-Hib® and HibTITER®
(againstHaemophilus influenzae type B, Hib), and the multivalent
pneumococcal conjugate Prevnar™ (12).
The widespread use of diphtheria toxoid and CRM197 has
prompted many investigations of DT and related proteins.
Diphtheria toxin is an ADP-ribosylating enzyme that is secreted
as a proenzyme of 535 residues and is processed by trypsin-like
proteases with release of two fragments (A and B). Fragment
A uses NAD as a substrate, catalyzing the cleavage of the N-
glycosidic bond between the nicotinamide ring and the N-ribose
and mediating the covalent transfer of the ADP-ribose (ADPRT
activity) to the modified Histidine 715 (diphthamide) of the elon-
gation factor EF-2. This posttranslational diphthamide modifica-
tion inactivates EF-2, halting protein synthesis and resulting in
cell death. Extensive structural studies elucidated the molecular
architecture of DT (13–19). The A fragment of DT (also named
C domain) carries the catalytic active site and is the only fragment
of the toxin required for the final step of intoxication, while the B
fragment carries the R and T domains, which mediate binding to
receptors on the host cell surface and promote the pH-dependent
transfer of fragment A to the cytoplasm, respectively. An Argi-
nine-rich disulfide-linked loop connects fragment A to fragment
B (or domain C to domains TR), and this interchain disulfide
bond is the only covalent link between the two fragments after
proteolytic cleavage of the chain at position 186.
While much progress has been made on the molecular char-
acterization of DT over the last two decades, an understanding
of the molecular basis for the lack of toxicity of CRM197 has
so far been elusive. Here we present the crystal structures of full-
length nucleotide-free (NF)-CRM197, and of CRM197 in com-
plex with the NAD hydrolysis product nicotinamide (NCA). In
addition, the differences between CRM197 and DT were eluci-
dated using surface plasmon resonance (SPR), a NAD-glycohy-
drolase (NADase) activity assay, molecular dynamics (MD)
simulations, and differential scanning fluorimetry (DSF).
Results
Overall Structure of Nucleotide-Free-CRM197.Crystals of a noncova-
lent dimer of CRM197 were obtained at pH 9 after freezing the
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protein in PBS buffer as previously reported for crystal forms III
and IV of DT (20). The first crystal structure of DT was also
solved as a noncovalent dimer that was later shown to be a non-
toxic form. This arose as an artifact of freezing the toxin in
sodium phosphate (21, 22). The structure of NF-CRM197 was
solved at 2-Å resolution by molecular replacement using as input
model the coordinates of NF-DT (PDB ID code 1SGK) (18). The
asymmetric unit contains one molecule of CRM197, which inter-
acts with a second (symmetry-related) molecule by “domain
swapping” (Fig. 1A and Fig. S1), as observed previously in di-
meric DT (23). Thus, the monomer of CRM197 has an “open”
conformation, where an individual monomer is noncovalently as-
sociated to a second chain by swapping of their R domains
(Fig. S1B). Nonetheless, the swapping of the R domains makes
the assembled CT domains from one chain and the R domain
from the second chain virtually identical to the monomeric
“closed” DT reported previously (13) (Fig. S1C).
The overall fold of NF-CRM197 is nearly equivalent to the
fold of a monomer from dimeric NF-DT, with an overall rmsd of
0.5 Å for 498 equivalent Cα atoms (Fig. 1A). Therefore, no major
conformational changes affecting the overall fold were observed
when comparing the apo-structure of CRM197 to DT.
Active-Site Loop of Nucleotide-Free-CRM197 and position of Gluta-
mate 52. Electron-density maps were of excellent overall quality,
readily allowing model building of CRM197. One region of major
interest partly lacking electron density is the active-site loop
(CL2) of the C domain (Fig. 1B). In DT, this loop is positioned
over the NAD-binding pocket and is thought to be important for
access of NAD to the binding cleft and for EF-2 recognition (16).
In NF-CRM197, there is no electron density for the CL2 loop
residues 38–49, while clear density resumes for the backbone
atoms of the flanking residues K37 and W50, suggesting that dis-
location of the active-site loop takes place upon the substitution
G52E. In summary, although NF-CRM197 has an overall fold
virtually identical to NF-DT, one major difference is observed in
the displacement of the active-site loop that covers the NAD-
binding pocket of DT.
Structure of Nicotinamide-CRM197. Despite previous reports that
CRM197 has a significantly lower affinity for NAD when com-
pared with DT (24–28), comparisons of NF-DT and NAD-DT
with NF-CRM197 show that, except for the disordered active-
site loop, the NAD-binding pocket is precisely maintained in
CRM197. This was confirmed by superimposing the A fragment
of CRM197 on the corresponding residues of NF-DT (1SGK)
(rmsd of 0.4 Å for 171 aligned Cα atoms) or on those of NAD-
DT (1TOX) (rmsd 0.5 Å). Therefore, the apo-structure presented
herein suggested that CRM197 might also be expected to bind
NAD. To assess this possibility, an excess of NAD (5 mM) was
Fig. 1. NF- and NCA-CRM197. (A) CRM197 catalytic (C) (residues 1–187), transmembrane (T) (residues 201–384), and receptor (R) (residues 387–535) domains
are colored as light gray, dark gray, and red, respectively, and labeled. Nucleotide-free DT (PDB ID code 1SGK) is shown as yellow cartoon after superposition
onto nucleotide-free CRM197. The active-site loop (CL2) of DT is shown in blue. The symmetry-related, domain-swapped molecule that forms the dimer of
CRM197 is depicted using transparent cartoons. (B) Zoom into the superimposed catalytic domain only, showing the active-site loop (CL2) from DT in orange,
the position of E52 of CRM197 and G52 of DTas sticks with carbon atoms colored in gray and yellow, respectively. The Cα atoms of the last visible residues of the
disordered active-site loop of CRM197 (K37 and W50) are shown as spheres and colored in magenta. Nitrogen and oxygen atoms are colored in blue and red,
respectively. (C) NAD-bound DT (PDB ID code 1TOX) is depicted as yellow cartoon after superposition onto NCA-CRM197 that is colored by domains as in Fig. 1A.
NCA bound to CRM197 is shown as red sticks and labeled, and the last visible residues of the active-site loop of CRM197 and DTcomplexed with NAD are shown
as spheres and colored in magenta. (D) The NAD-binding site in CRM197 (gray) compared to DT (yellow). Residues known to be involved both in NAD-binding
(G22, T23, G34, Q36, Y54, Y65) or in catalysis (H21, E148) are shown as sticks for DT (carbon atoms in yellow) and CRM197 (carbon atoms in gray). E52 and G52 in
CRM197 and DT are shown as sticks, while last visible residues of the active-site loop in both NCA-CRM197 (K37, K51) and NAD-DT (P38, D47) are shown as
spheres and colored magenta. The NAD bound to DT is shown as sticks with carbon atoms colored in green, and nitrogen, oxygen, and phosphorous atoms,
colored in blue, red, and orange, respectively. The NCA bound to CRM197 is shown as red sticks and labeled.
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used to perform soaking experiments using crystals of NF-
CRM197. After soaking for approximately 5 min, crystals were
transferred to a cryo-protectant solution and flash cooled in li-
quid nitrogen at −180°C (see Methods).
The structure of CRM197 from crystals soaked with NAD was
solved at 2.0-Å resolution by molecular replacement using as
input model the coordinates of NF-DT (PDB ID code 1SGK).
The asymmetric unit contains two molecules of CRM197 in the
open conformation, interacting by “domain swapping” as de-
scribed above for NF-CRM197 and NF-DT. The overall structure
is highly similar to NF- and NAD-DT, and to NF-CRM197, with
rmsds of 0.5 Å in all cases, comparing 501 and 494 identical Cα
atoms, respectively (Fig. 1C). Also in this new crystal form, a lack
of electron density for the active-site loop residues 38–50 again
suggested a high degree of flexibility in this region of CRM197.
Molecular Details of the Nicotinamide-CRM197 Interaction. After the
first cycles of restrained refinement, clear peaks of 2Fo − Fc elec-
tron-density at a contour level of 1σ and of Fo − Fc at 3σ became
visible in the active-site region of CRM197 (Fig. S2). Super-
position of DT complexed with NAD (PDB ID code 1TOX)
was used as a guide to locate and model NAD into this additional
electron density and to verify if the NAD from soakings was in-
deed incorporated into the crystals of CRM197. Modeling and
refinement resulted in well-resolved electron density for NCA,
while electron density for the remaining ADP-ribose was diffuse
and thus difficult to interpret and model (Fig. S2). Group occu-
pancy refinement in PHENIX (29) was used after modeling ADP-
ribose or whole NAD in order to test if partial occupancy could
explain the ambiguous densities. However, this approach did
not result in improved maps. Therefore, only NCA was included
and refined in the final model, hereafter termed NCA-CRM197.
The remaining unexplained blobs of electron density are likely a
consequence of the presence of a mixture of substrate and hydro-
lyzed products in the catalytic pocket of CRM197.
Comparison of NCA-CRM197 and NAD-DT (PDB ID code
1TOX) reveals the NCA binding mode to be identical (Fig. 1D
and Fig. S2). Also, the position and relative orientations of
protein residues making contacts with NCA or directly involved
in the ADPRTactivity are conserved among DTand CRM197 as
shown from their superposition (Fig. 1D). Y54 and Y65 line the
catalytic cleft of DT, forming a hydrophobic groove that accom-
modates NCA. Y65 is essential for NAD binding (30), and as in
NAD-DT, it forms an aromatic stacking interaction with the ring
of NCA and Y54 (Fig. 1D). E148 is a catalytic residue, involved in
the cleavage of the N-glycosidic bond that releases nicotinamide
and ADP-ribose. The side chain of residue H21 forms hydrogen
bonds to NAD and to the backbone of DT and was previously
postulated to be involved in maintaining the structural integrity
of the NAD-binding pocket (18). Other residues known to be
directly or indirectly involved in NAD binding (G22, T23, G34,
Q36) (16) are topologically equivalent between CRM197 and
DT (Fig. 1D). In summary, the G52E mutation does not directly
affect the architecture of the NAD-binding pocket.
NAD Binding to CRM197 and DT. To verify and compare binding
of NAD to CRM197 and DT in solution, we measured the affinity
of both proteins for NAD by SPR (Fig. 2). Binding of NAD was
observed both for immobilized DT (Fig. 2A) and immobilized
CRM197 (Fig. 2B). However, a significant dose response to
increasing NAD concentration was observed only for DT, while
the binding of NAD to CRM197 was almost negligible. A steady-
state binding analysis of the NAD-DT interaction yielded an
equilibrium dissociation constant (KD) of 28 3 μM, which
matches the previously reported values (Fig. 2C) (31). In con-
trast, the lower response of immobilized CRM197 to increasing
concentrations of NAD resulted in data scattered within a low
resonance unit interval, which did not allow determination of
a binding affinity. Thus, although the structures reveal that
CRM197 possesses an intact active site, the SPR data show that
its ability to effectively bind NAD in solution is significantly re-
duced. These observations are in agreement with our initial struc-
ture-based hypothesis that the dislocation of the active-site loop
of CRM197, while not altering the overall architecture of the ac-
tive site, has a direct influence on the ability of CRM197 to bind
its substrate.
To support the structurally informed hypothesis of residual
NAD binding and cleavage by CRM197, we also measured the
ability of CRM197 to hydrolyse NAD in solution and compared
it to DT. A radioactive NADase activity assay was performed in
the presence or absence of the reducing agent dithiothreitol
(DTT). While DT shows comparable, high levels of NADase ac-
tivity both in the presence or absence of DTT (Fig. 3), CRM197 is
inactive in the presence, and partially active (approximately 80%)
in the absence of the reducing agent. Considering that crystals of
the complex NCA-CRM197 were obtained in nonreducing con-
ditions, this result is in support of a further destabilizing effect
by the reducing agent. The expected effect that DTT has on
CRM197, or DT, is to reduce the disulfide bond that holds to-
gether fragment A (C domain) and B (T/R domain). However,
Fig. 2. CRM197 has residual affinity for NAD. Increase of resonance units
upon binding of NAD to immobilized DT and CRM197 is shown in A and
B, respectively. The plateau line represents the steady-state equilibrium
phase of interactions between the proteins and NAD, whereas the decrease
in resonance from the plateau represents the dissociation phase. (C) Steady-
state analysis of NAD binding to DT.
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no release of fragment A can take place upon addition of DTT
alone; for this to happen, trypsin would also be required (24). On
the contrary, either in presence or absence of reducing agent, DT
is equally able to cleave NAD.
Together, the SPR and NADase data confirm the structural
observation that CRM197 has an intact NAD-binding pocket,
equivalent to that present in DT. CRM197 is still able to bind
NAD, although with significantly less affinity than DT and only
in the absence of a further destabilizing agent (i.e., reducing
agents that likely detach fragment A from fragment B without
fully releasing it) it is also able to hydrolyze NAD.
Molecular Dynamics of the Active-Site Loop and Overall Stability of
CRM197. In order to understand the direct influence of the G52E
substitution on the conformation of the active-site loop of
CRM197, we performed molecular dynamics simulations with
a time step of 2 fs. As initial coordinates for DTwe used NF-DT
(PDB ID Code 1SGK), while for CRM197 we modified the
NF-DT coordinates by mutating the residue G in position 52 to
E as observed in our crystal structures. Residues 38–52 of the
active-site loop in the structure of CRM197 have rmsd values
greater than 90% of the values for wild-type DT, supporting the
notion that this loop becomes more flexible as a direct conse-
quence of the G52E mutation. The enhanced flexibility of the
loop is associated with the loss of intraloop hydrogen bonds that
help to stabilize the native loop conformation in NF-DT. Hydro-
gen bonds between the backbone carbonyl of P38 and the side
chain NH of Q43 and between the backbone carbonyl of T42
and the Nε of K51 were observed with frequency greater than
50% in the NF-DT simulation and less than 15% in CRM197
(Fig. 4A). The loop destabilization is likely induced by the direct
impact of the G52E mutation on two neighboring tryptophan re-
sidues (W50 and W153), which surround residue 52 (Fig. 4B). In
the NF-DTstructure, W153 interacts with the active-site loop via
an H-bond between its side chain NεH and the backbone carbo-
nyl of Q43. Also, W153 is involved in hydrophobic interactions
with G52 and with the side chains of K37, I35, P38, Q43, and
F53 (Fig. 4A). The analysis of the MD trajectories demonstrates
that the frequency with which the bond between W153 and Q43
is formed is 40% in NF-DT but only 1.6% in NF-CRM197.
To evaluate if the disorder of the active-site loop might have
any direct influence on the overall stability of CRM197, we mea-
sured the thermal stability of CRM197 and DT by DSF, observing
a lower melting temperature (−10°C) for CRM197 (Fig. 5). This,
together with the SPR and MD data above, suggests that the
G52E mutation contributes not only to the conformational flex-
ibility of the active-site loop and the reduced affinity for NAD,
but it also has an influence on the overall stability of CRM197.
Discussion
An explanation for the lack of toxicity in CRM197 has eluded
scientists since it was discovered that the difference from DT
is the single amino acid substitution G52E (8). G52 was already
known as a noncatalytic residue, and the crystal structures of
DT showed that residue G52 is not directly involved in either
NAD binding or EF-2 recognition. However, several biochemical
experiments supported the notion of conformational differences
between CRM197 and DT. For example, CRM197 and DTwere
shown to possess different susceptibilities to proteolysis (32);
monoclonal antibodies against CRM197 showed different bind-
ing properties when compared with binding to DT (33); CRM197
was also shown to be less stable in the cytoplasm than DT (34);
and ATP was shown to bind to DT inhibiting binding to the re-
ceptors (28) but not to CRM197 (35). However, more recent
studies also showed that CRM197 overexpression in the cytosol
can be toxic to the cell and may be able to weakly inhibit protein
synthesis (36–38).
Fig. 4. Active-site loop conformation of CRM197 sampled byMD. (A) The active-site loop of NF-DT (PDB ID code 1SGK) is shown in orange. Residues of the loop
involved in hydrogen bonds (P38, T42, K51, W153) are shown in sticks with carbon atoms colored in yellow, and the H-bond shown with dashes. Residues of the
active site (I35, K37, F53) contributing to a hydrophobic environment around W153 are also shown as sticks. As reference, the NAD from the complex NAD-DT
(PDB ID code 1TOX) is superimposed on NF-DTand shown as sticks in the background with carbon atoms colored in green. (B) Reoriented view of the active site.
NF-CRM197 and NCA-CRM197 are shown in gray, after superposition on NF-DT (yellow). W50, G52, E52, andW153 from NF-DT, and from NCA-CRM197 and NF-
CRM197 are shown in sticks with carbon atoms colored in yellow and gray for DTand CRM197, respectively. OE1 and OE2 atoms of E52 of CRM197 are shown as
dots.
Fig. 3. CRM197 in nonreducing conditions has NAD-glycohydrolase activity.
The NAD-glycohydrolase activity of DT (20 μg) and CRM197 (20 μg) was car-
ried out in 50 mM potassium phosphate, pH 7.5, 0.1 mM [carbonyl-14C]NAD
(0.05 μCi) in a total volume of 0.15 ml. The activity was measured in the pre-
sence (black bars) or in the absence (gray bars) of 50 mM DTT. Samples (50 μL)
after incubation at 37 C for 18 h were applied to 1-mL column of Dowex AG 1-
X2 and 14C-nicotinamide eluted with 5 mL of H2O for liquid scintillation
counting. NAD-glycohydrolase is expressed as nmol/h/mg and the incorpo-
rated radioactivity was measured in a Packard Top counter. ND, not detect-
able. Data are the means SD of values from two independent experiments.
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The crystal structures of CRM197 presented here show that
the only difference with DT is in the conformation of the active-
site loop in front of the NAD-binding site. While this loop was
previously observed well ordered in the structure NF-DT (18)
and disordered in the complex NAD-DT (16), CRM197 shows
an intrinsic flexibility of this region regardless of the presence
or absence of substrate. In addition to an identical overall fold,
CRM197 and DT also have an identical organization and archi-
tecture of the NAD-binding site, and accordingly the co-crystal
structure NCA-CRM197 shows that CRM197 is still able to hy-
drolyze NAD and release NCA, which binds to CRM197 in an
equivalent way to the complex NAD-DT.
One consequence of the flexible active-site loop of CRM197
is a reduced ability to bind NAD. Partially in agreement with
previous studies, SPR shows that CRM197 has much lower affi-
nity for NAD than DT. However, confirming the structural obser-
vations of a somewhat catalytically competent CRM197, NAD
hydrolysis by CRM197 in solution could be detected, but only
in nonreducing condition (same as the co-crystal structure con-
ditions). It is likely that an already destabilized CRM197 becomes
completely inactive when DTT, reducing the interfragment
disulfide bond between fragments A and B, introduces further
instability in the domain organization of CRM197. Despite the
instability caused by the G52E mutation and the ensuing ac-
tive-site loop flexibility, in the absence of DTT CRM197 is iden-
tical to the catalytically competent conformation of DT and
therefore able to hydrolyze NAD. As an additional verification,
we were unable to either obtain crystals of CRM197, or to mea-
sure any NADase activity, in the presence of the reducing agent
DTT.
Molecular dynamics simulations reveal the molecular basis for
the active-site loop disorder, which originates from the disruption
of hydrogen-bond interactions between W153 and the backbone
atoms of Q43 of the active-site loop. Notably, this translates into
appreciably less frequent H bonds in CRM197 between residues
of the active-site loop. A second tryptophan located nearby, W50,
is partially exposed to the solvent, and its indole side chain con-
tributes to form a hydrophobic pocket that accommodates the
catalytic residue E148 (Fig. 6). Mutagenesis of W50 and W153
to alanine has dramatic effects both on the ADPRTand NADase
activity of DT (39). The W50A mutant shows a decrease of
ADPRT activity by almost 105-fold and it completely abolishes
the NADase activity, while the W153A substitution shows an
approximately 40-fold and an approximately 10-fold decrease
of ADPRTand NADase activity, respectively. Instead, when the
tryptophans are mutated to phenylalanine, these mutants (W50F
and W153F) show only minimal reduction in both activities, con-
firming that aromatic stacking interactions play a significant role
in substrate binding.
Our structures show that in addition to introducing steric
clashes with the backbone of W50 (Fig. 4B), because G52 is
packed between the hydrophobic W50 and W153 (Fig. 4A and
Fig. 6) the polar side chain of E52 is displaced toward the solvent.
As a direct consequence, although this entire region is character-
ized by high flexibility, we can observe the dislodgment of the in-
dole side chain of W50 in NF-CRM197, which is almost 10 Å
distal to the same residue in DT (Fig. 4B).
An additional effect of the flexibility of the active-site loop is
overall instability of CRM197, as observed by DSF. This is in
agreement with the different properties of CRM197 and DT,
such as: different interaction with the toxin-receptors (24); less
stability in the cytosol (34); more susceptibility to proteases (32);
and almost complete lack of toxicity. However, because our data
show that there are no major conformational changes in the over-
all structure of the proteins but rather increased flexibility and
instability, it is not surprising that when highly expressed in the
reducing environment of the cytosol, CRM197 has residual toxi-
city (36–38).
Our results outline the molecular events that take place upon
mutation of Glycine 52 to Glutamate to produce CRM197,
providing experimental evidence for both localized and overall
destabilization. The combination of structural, dynamics, and
functional studies described in this work promote a better under-
standing of the differences between CRM197 and DT that make
CRM197 an ideal carrier protein for use in vaccine development.
Methods
Protein Production and Crystallization. CRM197 was obtained from Manufac-
turing of Novartis Vaccines and Diagnostics. Purified DTwas purchased from
Sigma-Aldrich Corporation. Purification and crystallization methods are out-
lined in SI Methods.
Data Collection and Structure Determination. Data were collected at beamline
5.0.3 of the ALS and both the structure of nucleotide-free and nicotinamide-
bound CRM197 were solved at 2.0 Å by molecular replacement in PHASER
(40). Data collection and refinement statistics are shown in Table S1. Figures
were generated with the program PYMOL (http://www.pymol.org). Details of
data collection and structure determination are described in SI Methods.
Surface Plasmon Resonance (SPR), Biacore. All SPR experiments were per-
formed using a Biacore T200 (GE Healthcare) equilibrated at 25 °C. Mono-
meric forms of DT and of CRM197 were immobilized on the sensor
surface and NAD (Sigma) was injected in running buffer. Full details of the
experimental setup, titration series, and data analysis methods are presented
in SI Methods.
NAD-Glycohydrolase Activity Assay. An enzymatic assay based on nicotina-
mide release was employed to measure the NAD-glycohydrolase activity
of monomeric CRM197 and DT (41). Full details are outlined in SI Methods.
Fig. 6. Hydrophobicity of the NAD-binding pocket of DT. NF-DT (1SGK) is
shown as gray surface and hydrophobic residues are colored using a scale
from light to bright orange. The superimposed NADmolecule from the struc-
ture NAD-DT (PDB ID code 1TOX) is shown as sticks with carbon, oxygen,
nitrogen, and phosphorous atoms colored in green, red, blue, and orange,
respectively. Residues W153, G52, W50, and E148 are shown as sticks under
the transparent surface, with carbon, oxygen, and nitrogen atoms colored in
yellow, red, and blue, respectively.
Fig. 5. CRM197 is less thermostable than DT. Thermal denaturation was in-
duced heating CRM197 and DT from 25 °C to 95 °C. CRM197 and DT displayed
Tm values of 44.3 °C and 55.2 °C respectively and 10.9 °C ΔTm , indicating a
greater stability of DT in comparison to CRM197.
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Molecular Dynamics Simulation. For the DT simulation we used the apo crystal
structure from PDB ID 1GSK. In order to set up the mutant simulation, the
residue G52 was substituted for E in 1SGK. The time step for integration
was 2 fs, and the coordinates of all atoms were saved every 5 ps. The full
protocol employed can be found in SI Methods.
Thermofluor Assay/Differential Scanning Fluorimetry. Full details of the experi-
mental setup are presented in SI Methods.
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